Metabolites: Have we MIST out the importance of structure and physicochemistry?

Bioanalysis

Volumn 2, Issue 7, 2010, Pages 1223-1232

  Smith, Dennis A ^a   Obach, R Scott ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 METHYL 5 [4 (1 PIPERAZINYLMETHYL)BENZAMIDO]ANILINO] 4 (3 PYRIDYL)PYRIMIDINE; DRUG METABOLITE; DRUG METABOLIZING ENZYME; ERLOTINIB; FEXOFENADINE; FLUOXETINE; FLUTAMIDE; GEFITINIB; GLUTATHIONE; HYDROXYFLUTAMIDE; IMATINIB; LAPATINIB; MORPHINE; NORFLUOXETINE; O NORTRAMADOL; QUINALDIC ACID; SUNITINIB; TAPENTADOL; TERFENADINE; TESTOSTERONE; TORCETRAPIB; TRAMADOL; DRUG;

BINDING AFFINITY; BIOLOGICAL ACTIVITY; CONCENTRATION (PARAMETERS); CONJUGATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; LIPOPHILICITY; MOLECULAR INTERACTION; MOLECULAR STABILITY; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SURFACE CHARGE; ANIMAL; BLOOD; CHEMISTRY; METABOLISM;

ANIMALS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHYSICOCHEMICAL PROCESSES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78651403237     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.92     Document Type: Review

References (30)

1. Sinsheimer JE, Dring LG, Williams RT. Species differences in the metabolism of norephedrine in man, rabbit and rat. Biochem. J. 136, 763-71 (1973).
2. Caldwell J, Dring LG, Williams RT. Metabolism of (14C)methamphetamine in man, the guinea pig and the rat. Biochem. J. 129, 11-22 (1972).
3. Park K, Williams DP, Naisbitt DJ et al. Investigation of toxic metabolites during drug development. Toxicol. Appl. Pharmacol. 207(2S), S425-S434 (2007)
4. Liebler DC, Guengerich FP. Elucidating mechanisms of drug-induced toxicity. Nat. Rev. Drug Discov. 4 (5), 410-420 (2005). (Pubitemid 40704124)
5. Guengerich FP. Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol. 21(1), 70-83 (2008). (Pubitemid 351219709)
6. Hastings KL, El-Hage J, Jacobs A et al. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 190(1), 91-2 (2003).
7. Davis-Bruno KL, Atrakchi AH. A regulatory perspective on issues and approaches in characterizing human metabolites. Chem. Res. Toxicol. 19(12), 1561-1563 (2006). (Pubitemid 44975118)
8. Atrakchi AH. Interpretation and considerations on the safety evaluation of human drug metabolites. Chem. Res. Toxicol. 22(7), 1217-1220 (2009).
9. Guengerich FP. Introduction: human metabolites in safety testing (MIST).Chem. Res. Toxicol. 22 (2), 237-238 (2009).
10. Smith DA, Obach RS. Seeing through the MIST. Commentary on metabolites in safety testing. Drug Metab. Dispos. 33(10), 1409-1417 (2005). (Pubitemid 41323986)
11. Smith DA, Obach RS, Williams DP, Park BK. Clearing the MIST (metabolites in safety testing) of time: the impact ofduration of administration on drug metabolite toxicity. Chem. Biol. Inter. 179(1), 60-67 (2009).
12. Smith DA, Obach RS. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem. Res. Toxicol. 22(2), 267-279 (2009).
13. Smith DA, Schmid EF. Drug withdrawals and the lessons within. Curr. Opin. Drug Discov. Develop. 9(1), 38-46 (2006). (Pubitemid 43099074)
14. Sanchez C, Hyttel J. Comparison of effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 19(4), 467-489 (1999). (Pubitemid 29283825)
15. Tuccinardi T, Calderone V, Rapposelli S, Martinelli A. Proposal of a new binding orientation for non-peptide AT1 antagonists: homology modelling, docking and three dimensional quantitative structure-activity relationship analysis. J. Mol. Chem. 499(14), 4305-4316 (2006). (Pubitemid 44036674)
16. van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat. Rev. 35(8), 692-706 (2009).
17. Deeks ED, Keating GM. Sunitib. Drugs. 66(17), 2255-2266 (2006).
18. McKillop D, Guy SP, Spence MP et al. Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. Xenobiotica 36(1), 29-39 (2006).
19. Cockerill S, Stubberfield C, Stables J et al. Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2. Bioorg. Med. Chem. Letts. 11(11), 1401-1405 (2001). (Pubitemid 32510830)
20. Price DA, Blagg J, Jones L et al. Physicochemical drug properties associated with in vivo toxicological outcomes: a review. Exp. Opin. Drug Met. Toxicol. 5(8), 921-931 (2009).
21. Hughes JD, Blagg J, Price DA et al. Physicochemical drug properties associated with in vivo toxicological outcomes. Biorg. Med. Chem. Letts. 18(17), 4872-4875 (2008).
22. Azzaoui K, Hamon J, Faller B et al. Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2(6), 874-880 (2007).
23. Peters JU, Schnider P, Mattei P, Kansy M. Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem. 4(4), 680-686 (2009).
24. Manner CN, Payling DW, Smith DA. Distribution coefficient, a convenient term for the relation of predictable physico-chemical properties to metabolic processes. Xenobiotica. 18(3), 331-350 (1988). (Pubitemid 18064590)
25. Heal D, Cheetham S, Martin K et al. Comparative pharmacology of dothiepin, its metabolites and other antidepressant drugs. Drug Develop. Res. 27(1), 121-135 (1992).
26. Dorn SB, Degan GH, Bolt HM et al. Some molecular desciptors for non-specific chromosomal genotoxicity based on hydrophobic interactions. Arch. Toxicol. 82(5), 333-338. 2008.
27. Dalvie D, Chen W, Zhang C et al. Pharmacokinetics, metabolism and excretion of torcetrapib, a cholesterol ester transfer protein inhibitor, in humans. Drug Met.Disp. 36(11), 2185-2198 (2008).
28. Kalgutkar AS, Didiuk MT. Structural alerts, reactive metabolites and protein covalent binding: how reliable are these attributes as predictors of drug toxicity. Chem. Biodivers. 6(11), 2115-2137 (2009).
29. Aronov M, McClain B, Moody CS, Murcko MA. Kinase-likeness and kinase privileged fragements: towards virtual polypharmacology. J. Med. Chem. 51(5), 1214-1222 (2008). (Pubitemid 351480383)
30. Ertl P, Rohde B, Selzer P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 43(20), 3714-3717 (2000).